ENHANCED SOLUBILITY AND DISSOLUTION BY SURFACE-MODIFIED SOLID DISPERSION OF ALECTINIB HYDROCHLORIDE
DOI:
https://doi.org/10.22159/ijap.2023v15i4.47851Keywords:
Poor solubility, Soluplus, Gelucire, Surface-modified solid dispersion, Biorelevant mediaAbstract
Objective: Alectinib hydrochloride (AH), a poorly soluble drug, exhibits low solubility thereby very low bioavailability. The present study aims to develop and optimize surface-modified solid dispersion of AH (AH-SMSD) with enhanced solubility and dissolution using Soluplus® (SOL) and Gelucire 44/14 (GEL) as a polymer and surfactant, respectively.
Methods: Design of Experiments (DoE) was implemented to optimize the weight ratio of SOL (X1), and GEL (X2), keeping the drug weight constant to maximize the solubility (Y1) and dissolution (Y2). The optimized solid dispersion was subjected to solubility and dissolution in bio-relevant media and characterized using differential scanning calorimetry (DSC), Powder X-ray diffraction (pXRD), Fourier-transform infrared (FTIR), and scanning electron microscopy (SEM).
Results: A statistically significant model is obtained for solubility and dissolution through DoE. Formulation (F9) containing AH: SOL: GEL in weight ratios 1:5:5 showed a 547-fold increase in solubility. This solubility enhancement further translated into dissolution improvement with drug release of >80% in 15 min. The optimized formulation also showed improved solubility and dissolution in fasted-state bio-relevant media. DSC and pXRD showed a change in the crystallinity pattern of the drug. FTIR showed the existence of weak intermolecular interactions. Morphological evaluation through SEM demonstrated that the drug particles were dispersed to a hydrophilic carrier matrix, thus, transforming the hydrophobic drug into a hydrophilic form.
Conclusion: AH-SMSD with enhanced solubility and dissolution was successfully developed. The optimized formulation also showed improvement in the bio-relevant media and therefore has the potential to improve in vivo oral bioavailability (however, needs to be experimentally explored).
Downloads
References
Larkins E, Blumenthal GM, Chen H, He K, Agarwal R, Gieser G. FDA approval: alectinib for the treatment of metastatic, ALK-positive non-small cell lung cancer following crizotinib. Clin Cancer Res. 2016 Nov 1;22(21):5171-6. doi: 10.1158/1078-0432.CCR-16-1293, PMID 27413075.
Morcos PN, Parrott N, Banken L, Timpe C, Lindenberg M, Guerini E. Effect of the wetting agent sodium lauryl sulfate on the pharmacokinetics of alectinib: results from a bioequivalence study in healthy subjects. Clin Pharmacol Drug Dev. 2017 May 1;6(3):266-79. doi: 10.1002/cpdd.299, PMID 27545871.
Morcos PN, Yu L, Bogman K, Sato M, Katsuki H, Kawashima K. Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects. Xenobiotica. 2017 Mar;47(3):217-29. doi: 10.1080/00498254.2016.1179821, PMID 27180975.
Parrott NJ, Yu LJ, Takano R, Nakamura M, Morcos PN. Physiologically based absorption modeling to explore the impact of food and gastric pH changes on the pharmacokinetics of alectinib. AAPS J. 2016 Nov 1;18(6):1464-74. doi: 10.1208/s12248-016-9957-3, PMID 27450228.
Australian public assessment reports (AusPAR). Woden: Therapeutic Goods Administration. Extract from the Clinical Evaluation Report for Alectinib; 26 Dec 2017. Available from: https://www.tga.gov.au/resources/auspar/auspar-alectinib-hydrochloride. [Last accessed on 18 Apr 2023]
Morcos PN, Guerini E, Parrott N, Dall G, Blotner S, Bogman K. Effect of food and esomeprazole on the pharmacokinetics of alectinib, a highly selective ALK inhibitor, in healthy subjects. Clin Pharmacol Drug Dev. 2017 Jul 1;6(4):388-97. doi: 10.1002/cpdd.296, PMID 27545320.
Drugs@FDA. Silver Spring: United States Food and Drug Administration. FDA-approved drugs; 03 Sep 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf.
Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN Pharm. 2012;2012:195727. doi: 10.5402/2012/195727. PMID 22830056.
Zhang X, Xing H, Zhao Y, Ma Z. Pharmaceutical dispersion techniques for dissolution and bioavailability enhancement of poorly water-soluble drugs. Pharmaceutics. 2018 Jun 23;10(3):74. doi: 10.3390/pharmaceutics10030074, PMID 29937483.
Kim DH, Kim YW, Tin YY, Soe MTP, Ko BH, Park SJ. Recent technologies for amorphization of poorly water-soluble drugs. Pharmaceutics. 2021 Aug 23;13(8):1308-18. doi: 10.3390/pharmaceutics13081318, PMID 34452279.
Kaushik R, Budhwar V, Kaushik D. An overview on recent patents and technologies on solid dispersion. Recent Pat Drug Deliv Formul. 2020 Jan 17;14(1):63-74. doi: 10.2174/1872211314666200117094406, PMID 31951172.
Nair AR, Lakshman YD, Anand VSK, Sree KSN, Bhat K, Dengale SJ. Overview of extensively employed polymeric carriers in solid dispersion technology. AAPS PharmSciTech. 2020;21(8)(8):309. doi: 10.1208/s12249-020-01849-z, PMID 33161493.
Tekade AR, Yadav JN. A review on solid dispersion and carriers used therein for solubility enhancement of poorly water-soluble drugs. Adv Pharm Bull. 2020 Jul;10(3):359-69. doi: 10.34172/apb.2020.044, PMID 32665894.
Tran P, Pyo YC, Kim DH, Lee SE, Kim JK, Park JS. Overview of the manufacturing methods of solid dispersion technology for improving the solubility of poorly water-soluble drugs and application to anticancer drugs. Pharmaceutics. 2019 Mar 19;11(3):132. doi: 10.3390/pharmaceutics11030132, PMID 30893899.
Hu XY, Lou H, Hageman MJ. Preparation of lapatinib ditosylate solid dispersions using solvent rotary evaporation and hot melt extrusion for solubility and dissolution enhancement. Int J Pharm. 2018 Dec 1;552(1-2):154-63. doi: 10.1016/j.ijpharm.2018.09.062, PMID 30268849.
Borawake PD, Arumugam K, Shinde JV. Formulation of solid dispersions for enhancement of solubility and dissolution rate of simvastatin. Int J Pharm Pharm Sci. 2021 Jul 1:94-100. doi: 10.22159/ijpps.2021v13i7.41205.
Shamma RN, Basha M. Soluplus®: A novel polymeric solubilizer for optimization of carvedilol solid dispersions: formulation design and effect of method of preparation. Powder Technol. 2013 Mar;237:406-14. doi: 10.1016/j.powtec.2012.12.038.
Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water-soluble drugs. Drug Discov Today. 2007 Dec;12(23-24):1068-75. doi: 10.1016/j.drudis.2007.09.005, PMID 18061887.
Sarkar P, Das S, Majee SB. Solid dispersion tablets in improving oral bioavailability of poorly soluble drugs. Int J Curr Pharm Sci. 2022 Mar 15:15-20. doi: 10.22159/ijcpr.2022v14i2.1961.
Park YJ, Oh DH, Yan YD, Seo YG, Lee SN, Choi HG. Surface-attached solid dispersion. J Pharm Investig. 2010 May 15;40:97-102. doi: 10.4333/KPS.2010.40.S.097.
Park JH, Cho JH, Kim DS, Kim JS, Din FU, Kim JO. Revaprazan-loaded surface-modified solid dispersion: physicochemical characterization and in vivo evaluation. Pharm Dev Technol. 2019 Jul 3;24(6):788-93. doi: 10.1080/10837450.2019.1597114, PMID 30885016.
Alshahrani SM, Lu W, Park JB, Morott JT, Alsulays BB, Majumdar S. Stability-enhanced hot-melt extruded amorphous solid dispersions via combinations of Soluplus® and HPMCAS-HF. AAPS PharmSciTech. 2015 Aug 25;16(4):824-34. doi: 10.1208/s12249-014-0269-6, PMID 25567525.
Caron V, Hu Y, Tajber L, Erxleben A, Corrigan OI, McArdle P. Amorphous solid dispersions of sulfonamide/Soluplus® and sulfonamide/PVP prepared by ball milling. AAPS PharmSciTech. 2013 Mar;14(1):464-74. doi: 10.1208/s12249-013-9931-7, PMID 23389838.
Tian B, Ju X, Yang D, Kong Y, Tang X. Effect of the third component on the aging and crystallization of cinnarizine-soluplus® binary solid dispersion. Int J Pharm. 2020 Apr 30;580:119240. doi: 10.1016/j.ijpharm.2020.119240, PMID 32197983.
BASF Pharma. Technical information-surplus. Florham Park: BASF Corporation; 2019. Available from: https://pharma.basf.com/products/soluplus [Last accessed on 18 Apr 2023].
Liu P, Zhou JY, Chang JH, Liu XG, Xue HF, Wang RX. Soluplus-mediated diosgenin amorphous solid dispersion with high solubility and high stability: development, characterization and oral bioavailability. Drug Des Devel Ther. 2020;14:2959-75. doi: 10.2147/DDDT.S253405, PMID 32801637.
Zi P, Zhang C, Ju C, Su Z, Bao Y, Gao J. Solubility and bioavailability enhancement study of lopinavir solid dispersion matrixed with a polymeric surfactant–soluplus. Eur J Pharm Sci. 2019 Jun 15;134:233-45. doi: 10.1016/j.ejps.2019.04.022, PMID 31028820.
Lu J, Cuellar K, Hammer NI, Jo S, Gryczke A, Kolter K. Solid-state characterization of felodipine-soluplus amorphous solid dispersions. Drug Dev Ind Pharm. 2016 Jan 1;42(3):485-96. doi: 10.3109/03639045.2015.1104347, PMID 26530290.
da Fonseca Antunes AB, De Geest BG, Vervaet C, Remon JP. Gelucire 44/14 based immediate release formulations for poorly water-soluble drugs. Drug Dev Ind Pharm. 2013 May;39(5):791-8. doi: 10.3109/03639045.2012.709251, PMID 22871141.
Karataş A, Yuksel N, Baykara T. Improved solubility and dissolution rate of piroxicam using gelucire 44/14 and Labrasol. Farmaco. 2005 Sep;60(9):777-82. doi: 10.1016/j.farmac.2005.04.014, PMID 16084514.
Yüksel N, Karatas A, Ozkan Y, Savaşer A, Ozkan SA, Baykara T. Enhanced bioavailability of piroxicam using gelucire 44/14 and Labrasol: in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2003 Nov;56(3):453-9. doi: 10.1016/s0939-6411(03)00142-5, PMID 14602190.
Saha SK, Joshi A, Singh R, Jana S, Dubey K. An investigation into solubility and dissolution improvement of alectinib hydrochloride as a third-generation amorphous solid dispersion. J Drug Deliv Sci Technol. 2023 Feb 9;81:104259. doi: 10.1016/j.jddst.2023.104259.
Klein S. The use of biorelevant dissolution media to forecast the in vivo performance of a drug. AAPS J. 2010 Sep;12(3):397-406. doi: 10.1208/s12248-010-9203-3, PMID 20458565.
Rehman S, Nabi B, Fazil M, Khan S, Bari NK, Singh R. Role of P-glycoprotein inhibitors in the bioavailability enhancement of solid dispersion of darunavir. BioMed Res Int. 2017;2017:8274927. doi: 10.1155/2017/8274927, PMID 29226149.
Rangel Yagui CO, Pessoa A, Tavares LC. Micellar solubilization of drugs. J Pharm Pharm Sci. 2005 Jul 8;8(2):147-65. PMID 16124926.
Mai NNS, Otsuka Y, Kawano Y, Hanawa T. Preparation and characterization of solid dispersions composed of curcumin, hydroxypropyl cellulose and/or sodium dodecyl sulfate by grinding with vibrational ball milling. Pharmaceuticals (Basel). 2020 Nov 1;13(11):1-15. doi: 10.3390/ph13110383, PMID 33198284.
Vats SK, Gupta RN, Ramaraju K, Singh R. Design and statistical evaluation of a multiunit delivery system containing nisoldipine-soluplus® solid dispersion for hypertension chronotherapy. Int J Pharm Pharm Sci. 2016;8(10):170-7. doi: 10.22159/ijpps.2016v8i10.13442.
Boyd BJ, Bergstrom CAS, Vinarov Z, Kuentz M, Brouwers J, Augustijns P. Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems. Eur J Pharm Sci. 2019 Sep 1;137:104967. doi: 10.1016/j.ejps.2019.104967, PMID 31252052.
Linn M, Collnot EM, Djuric D, Hempel K, Fabian E, Kolter K. Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo. Eur J Pharm Sci. 2012 Feb 14;45(3):336-43. doi: 10.1016/j.ejps.2011.11.025, PMID 22172603.
He Y, Johnson JLH, Yalkowsky SH. Oral formulation of a novel antiviral agent, PG301029, in a mixture of gelucire 44/14 and DMA (2:1, wt/wt). AAPS PharmSciTech. 2005 Apr 8;6(1):E1-5. doi: 10.1208/pt060101, PMID 16353952.
Giri BR, Kim JS, Park JH, Jin SG, Kim KS, Din FU. Improved bioavailability and high photostability of methotrexate by spray-dried surface-attached solid dispersion with an aqueous medium. Pharmaceutics. 2021 Jan 16;13(1):111. doi: 10.3390/pharmaceutics13010111, PMID 33467157.
Pinto JMO, Rengifo AFC, Mendes C, Leao AF, Parize AL, Stulzer HK. Understanding the interaction between Soluplus® and biorelevant media components. Colloids Surf B Biointerfaces. 2020 Mar 1;187:110673. doi: 10.1016/j.colsurfb.2019.110673, PMID 31812452.
Lakshman D, Chegireddy M, Hanegave GK, Sree KN, Kumar N, Lewis SA. Investigation of drug-polymer miscibility, biorelevant dissolution, and bioavailability improvement of dolutegravir-polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer solid dispersions. Eur J Pharm Sci. 2020 Jan 15;142:105137. doi: 10.1016/j.ejps.2019.105137, PMID 31706016.
Radke R, Jain NK. Enhancement of solubility and bioavailability of BCS class-II ambrisentan: in vitro, in vivo and ex vivo analysis. Int J App Pharm. 2022 Jan 1;14(1):67-74. doi: 10.22159/ijap.2022v14i1.43347.
Aparna TN, Siva Rao ASS. Formulation, in vitro and in vivo evaluation of palbociclib solid dispersions. Int J App Pharm. 2022 Sep 1;14(5):144-52. doi: 10.22159/ijap.2022v14i5.43992.
Colombo M, de Lima Melchiades G, Michels LR, Figueiro F, Bassani VL, Teixeira HF. Solid dispersion of kaempferol: formulation development, characterization, and oral bioavailability assessment. AAPS PharmSciTech. 2019 Feb 11;20(3):106. doi: 10.1208/s12249-019-1318-y, PMID 30746582.
Lee SN, Poudel BK, Tran TH, Marasini N, Pradhan R, Lee YI. A novel surface-attached carvedilol solid dispersion with enhanced solubility and dissolution. Arch Pharm Res. 2013 Jan;36(1):79-85. doi: 10.1007/s12272-013-0008-7, PMID 23328872.
Sarpal K, Munson EJ. Amorphous solid dispersions of felodipine and nifedipine with Soluplus®: drug-polymer miscibility and intermolecular interactions. J Pharm Sci. 2021 Apr 1;110(4):1457-69. doi: 10.1016/j.xphs.2020.12.022, PMID 33359813.
Li DX, Jang KY, Kang W, Bae K, Lee MH, Oh YK. Enhanced solubility and bioavailability of sibutramine base by solid dispersion system with an aqueous medium. Biol Pharm Bull. 2010;33(2):279-84. doi: 10.1248/bpb.33.279, PMID 20118553.
Joe JH, Lee WM, Park YJ, Joe KH, Oh DH, Seo YG. Effect of the solid-dispersion method on the solubility and crystalline property of tacrolimus. Int J Pharm. 2010 Aug;395(1-2):161-6. doi: 10.1016/j.ijpharm.2010.05.023, PMID 20580799.
Published
How to Cite
Issue
Section
Copyright (c) 2023 SUMIT KUMAR SAHA, AMITA JOSHI, ROMI SINGH, KIRAN DUBEY
This work is licensed under a Creative Commons Attribution 4.0 International License.
